ALCLS.PA PAR
Cellectis S.A.
1W: +0.0%
1M: -57.6%
3M: -54.2%
YTD: -63.0%
1Y: -45.4%
3Y: -29.0%
5Y: -89.4%
€1.25 ($1.41)
-0.04 (-2.79%)
Weekly Expected Move ±24.6%
€1
€1
€1
€2
€2
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
#12
of 32
Biotechnology
Technical Signal Map
0 Bullish
0 Neutral
13 Bearish
ALCLS.PA
$90M
Cellectis S.A.
BEARISH
-91
GNFTF
$790M
Genfit S.a.
LEAN BEAR
-20
MEDCL.PA
$1.2B
MedinCell S.A.
BEARISH
-42
IVA
$760M
Inventiva S.A.
BEARISH
-82
NANO.PA
$1.4B
Nanobiotix S.A.
BEARISH
-84
GNFT.PA
$470M
Genfit S.A.
BEARISH
-84
ALVIO.PA
$260M
Valerio Therapeutics S.A.
BEARISH
-84
IPH.PA
$150M
Innate Pharma S.A.
BEARISH
-87
TNG.PA
$200M
Transgene S.A.
BEARISH
-91
ABVX
$10B
Abivax S.A.
BEARISH
-100
VLA.PA
$640M
Valneva SE
BEARISH
-100
DBVT
$330M
DBV Technologies S.A.
BEARISH
-100
OSE.PA
$100M
OSE Immunotherapeutics S.A.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| ALCLS.PA Cellectis S.A. | $90M | -2.2 | -94.5 | 117.1 | -417.3 | 0.5 | 2 | BEARISH | -45.4 |
| GNFTF Genfit S.a. | $790M | -4.5 | -575.3 | -453.0 | -124.0 | 1.4 | 4 | LEAN BEAR | 323.4 |
| MEDCL.PA MedinCell S.A. | $1.2B | -24.4 | 263.4 | 117.9 | -192.3 | 118.3 | 6 | BEARISH | 29.4 |
| IVA Inventiva S.A. | $760M | -5.9 | 5561.1 | 482.3 | -347355.8 | -73.5 | 4 | BEARISH | -39.8 |
| NANO.PA Nanobiotix S.A. | $1.4B | -20.8 | 378.9 | 158.1 | -941.2 | -74.7 | 3 | BEARISH | 191.2 |
| GNFT.PA Genfit S.A. | $470M | -4.5 | -577.1 | -452.8 | -124.0 | 5.6 | 4 | BEARISH | 163.8 |
| ALVIO.PA Valerio Therapeutics S.A. | $260M | -16.1 | -341.6 | -159.1 | -191.7 | 142.6 | 3 | BEARISH | 731.7 |
| IPH.PA Innate Pharma S.A. | $150M | -2.6 | 1596.8 | 263.8 | -630.0 | -82.3 | 2 | BEARISH | -28.3 |
| TNG.PA Transgene S.A. | $200M | -4.2 | -130.2 | -325.5 | -5760.7 | -61.1 | 4 | BEARISH | -38.6 |
| ABVX Abivax S.A. | $10B | -17.7 | -243.7 | 933.2 | — | 64.6 | 4 | BEARISH | 12.7 |
| VLA.PA Valneva SE | $640M | -2.8 | -117.8 | -57.6 | -89.3 | -27.2 | 1 | BEARISH | -33.8 |
| DBVT DBV Technologies S.A. | $330M | -2.7 | -142.6 | -2201.5 | — | -100.0 | 2 | BEARISH | 4.8 |
| OSE.PA OSE Immunotherapeutics S.A. | $100M | -1.3 | -1.0 | -42.4 | -1743.4 | 319.0 | 5 | BEARISH | -65.6 |
| ALCLS.PA Cellectis S.A. | $90M | -2.2 | -94.5 | 117.1 | -417.3 | 0.5 | 2 | BEARISH | -45.4 |
| GNFTF Genfit S.a. | $790M | -4.5 | -575.3 | -453.0 | -124.0 | 1.4 | 4 | LEAN BEAR | 323.4 |
| MEDCL.PA MedinCell S.A. | $1.2B | -24.4 | 263.4 | 117.9 | -192.3 | 118.3 | 6 | BEARISH | 29.4 |
| IVA Inventiva S.A. | $760M | -5.9 | 5561.1 | 482.3 | -347355.8 | -73.5 | 4 | BEARISH | -39.8 |
| NANO.PA Nanobiotix S.A. | $1.4B | -20.8 | 378.9 | 158.1 | -941.2 | -74.7 | 3 | BEARISH | 191.2 |
| GNFT.PA Genfit S.A. | $470M | -4.5 | -577.1 | -452.8 | -124.0 | 5.6 | 4 | BEARISH | 163.8 |
| ALVIO.PA Valerio Therapeutics S.A. | $260M | -16.1 | -341.6 | -159.1 | -191.7 | 142.6 | 3 | BEARISH | 731.7 |
| IPH.PA Innate Pharma S.A. | $150M | -2.6 | 1596.8 | 263.8 | -630.0 | -82.3 | 2 | BEARISH | -28.3 |
| TNG.PA Transgene S.A. | $200M | -4.2 | -130.2 | -325.5 | -5760.7 | -61.1 | 4 | BEARISH | -38.6 |
| ABVX Abivax S.A. | $10B | -17.7 | -243.7 | 933.2 | — | 64.6 | 4 | BEARISH | 12.7 |
| VLA.PA Valneva SE | $640M | -2.8 | -117.8 | -57.6 | -89.3 | -27.2 | 1 | BEARISH | -33.8 |
| DBVT DBV Technologies S.A. | $330M | -2.7 | -142.6 | -2201.5 | — | -100.0 | 2 | BEARISH | 4.8 |
| OSE.PA OSE Immunotherapeutics S.A. | $100M | -1.3 | -1.0 | -42.4 | -1743.4 | 319.0 | 5 | BEARISH | -65.6 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
ALCLS.PA vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F